DOCSLIB.ORG

LABA/LAMA Fixed-Dose Combinations in Patients with COPD: a Systematic Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LABA/LAMA Fixed-Dose Combinations in Patients with COPD: a Systematic Review Journal name: International Journal of COPD Article Designation: Review Year: 2018 Volume: 13 International Journal of COPD Dovepress Running head verso: Rogliani et al Running head recto: LABA/LAMA in COPD open access to scientific and medical research DOI: 170606 Open Access Full Text Article REVIEW LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review 1 Paola Rogliani Objectives: The aim of this study was to assess the current evidence for long-acting β2-agonist Luigino Calzetta1 (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) in the Fulvio Braido2 treatment of COPD. Mario Cazzola1 Materials and methods: A systematic literature search of randomized controlled trials pub- Enrico Clini3 lished in English up to September 2017 of LABA/LAMA FDCs vs LABA or LAMA or LABA/ Girolamo Pelaia4 inhaled corticosteroid (ICS) FDCs in COPD patients was performed using PubMed, Embase, Scopus, and Google Scholar. Outcomes including forced expiratory volume in 1 second (FEV ), Andrea Rossi5 1 Transition Dyspnea Index (TDI) scores, St George’s Respiratory Questionnaire (SGRQ) scores, Nicola Scichilone6 exacerbations, exercise tolerance (endurance time [ET]), inspiratory capacity (IC), and rescue 7 Fabiano Di Marco medication use were evaluated. 1Department of Experimental Results: In total, 27 studies were included in the review. LABA/LAMA FDCs significantly Medicine and Surgery, University improved lung function (FEV ) at 12 weeks compared with LABA or LAMA or LABA/ICS. of Rome Tor Vergata, Rome, Italy; 1 2Department of Internal Medicine, These effects were maintained over time. Significant improvements with LABA/LAMA FDCs IRCCS San Martino Genoa University vs each evaluated comparator were also observed in TDI and SGRQ scores, even if significant Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, differences between different LABA/LAMA FDCs were detected. Only the LABA/LAMA FDC University of Modena and Reggio indacaterol/glycopyrronium has shown superiority vs LAMA and LABA/ICS for reducing exac- 4 Emilia, Modena, Italy; Department erbation rates, while olodaterol/tiotropium and indacaterol/glycopyrronium have been shown to of Medical and Surgical Sciences, Section of Respiratory Diseases, improve ET and IC vs the active comparators. Rescue medication use was significantly reduced Magna Græcia University, Catanzaro, by LABA/LAMA FDCs vs the evaluated comparators. LABA/LAMA FDCs were safe, with no 5 Italy; Pulmonary Unit, University of increase in the risk of adverse events with LABA/LAMA FDCs vs the monocomponents. Verona, Verona, Italy; 6Department of Internal Medicine, University of Conclusion: Evidence supporting the efficacy of LABA/LAMA FDCs for COPD is heteroge- Palermo, Palermo, Italy; 7Department neous, particularly for TDI and SGRQ scores, exacerbation rates, ET, and IC. So far, indacaterol/ of Health Sciences, Università glycopyrronium is the LABA/LAMA FDC that has the strongest evidence for superiority vs degli Studi di Milano, Respiratory Unit, Papa Giovanni XXIII Hospital, LABA, LAMA, and LABA/ICS FDCs across the evaluated outcomes. LABA/LAMA FDCs were Bergamo, Italy safe; however, more data should be collected in a real-world setting to confirm their safety. Keywords: LABA, LAMA, fixed-dose combination, COPD, systematic review Introduction COPD is a chronic disease characterized by not fully reversible, commonly progressive airflow limitation. According to the WHO estimates, 65 million people have moderate- to-severe COPD worldwide. In 2005, COPD-related deaths accounted for 5% of worldwide deaths; the data certainly underestimated as the most epidemiological Correspondence: Paola Rogliani data that originate exclusively from high-income countries.1 Based on current figures, Department of Experimental Medicine WHO predicts a 30% increase in COPD deaths over the next 10 years, which will and Surgery, University of Rome Tor Vergata, Via Montpellier 1, make COPD the third highest cause of death worldwide by 2030.1 Rome 00133, Italy Guidelines and recommendations aim at assisting physicians during the process Tel +39 062 090 4656 Email [email protected] of diagnosis and disease management so that any single COPD patient may receive submit your manuscript | www.dovepress.com International Journal of COPD 2018:13 3115–3130 3115 Dovepress © 2018 Rogliani et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you http://dx.doi.org/10.2147/COPD.S170606 hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Rogliani et al Dovepress the most appropriate medical care by adhering to evidence- Search strategy based medicine. Bronchodilators are the mainstay of COPD This systematic review has been registered in PROSPERO treatment. Long-acting β2-agonists (LABAs) or ultra-LABAs (registration number: CRD42017070930; https://www.crd. and long-acting muscarinic antagonists (LAMAs) are the york.ac.uk/prospero/display_record.php?RecordID=70930) preferred options for patients at different stages of the disease. and performed in agreement with the Preferred Reporting Indeed, the most recent update of the Global Initiative for Items for Systematic Reviews and Meta-Analyses (PRISMA) Chronic Obstructive Lung Disease (GOLD) recommenda- statement (Figure 1).7 This systematic review satisfied all tions states that 1) LABAs and LAMAs significantly improve the recommended items reported by the PRISMA-P 2015 lung function and dyspnea health status, and reduce exacerba- checklist.8 tion rates, and 2) combination treatment with LABA/LAMA We undertook a comprehensive literature search for RCTs increases forced expiratory volume in 1 second (FEV1) and published in English and looking at the impact of LABA/ reduce COPD symptoms compared with monotherapy.2 Both LAMA FDCs in patients with COPD. The search was per- statements are provided with the highest strength of recom- formed in PubMed, Embase, Scopus, and Google Scholar mendation according to the level of evidence (level A).2 through to September 2017, in order to provide for relevant Benefits of LABA/LAMA fixed-dose combinations (FDCs) studies available up to September 30, 2017. are widely reported;3–5 however, the availability of different The terms “aclidinium,” “formoterol,” “glycopyrronium,” FDC options approved for the treatment of COPD and the “glycopyrrolate,” “indacaterol,” “olodaterol,” “salmeterol,” absence of head-to-head studies between all the available “tiotropium,” “umeclidinium,” and “vilanterol” were searched LABA/LAMA FDCs make choosing the most appropriate for the FDCs, and the term “chronic obstructive pulmonary option difficult. disease” OR “COPD” was searched for the disease. Therapeutic choice always depends on the evaluation of Studies reporting the impact of the currently approved biological characteristics of the disease, symptoms, previous doses (European Medicines Agency and/or the United States therapies and responses to them, health status, and last but Food and Drug Administration dosing) of LABA/LAMA not least patient preference. Therefore, the optimal therapy FDCs vs LABAs or LAMAs or LABA/inhaled corticosteroid is the one drawn on the medical history of each patient. (ICS) FDCs on lung function (trough and peak FEV1), dysp- However, results from clinical trials, clinical practice, and nea (assessed using Transition Dyspnea Index [TDI] scores), guidelines are essential for an evidence-based medicine quality of life (assessed using St George’s Respiratory Ques- approach. tionnaire [SGRQ] scores), COPD exacerbation rates, exercise Patients’ characteristics such as age, cognitive status, tolerance (assessed by endurance time [ET]), inspiratory visual acuity, manual dexterity, manual strength, and coor- capacity (IC), and the use of rescue medication were included dination may influence the correct use of inhaler devices and, in this systematic review. Two reviewers independently thus, the efficacy of inhaled medications. In fact, for several checked the relevant studies identified from literature searches patients using a nebulizer, a pressurized metered dose inhaler and databases. The studies were selected in agreement or a dry powder inhaler device provides an easy-to-use and with the previously mentioned criteria, and any difference cost-effective therapy.6 in opinion about eligibility was resolved by consensus. This review will systematically and critically examine the available evidence on marketed LABA/LAMA FDCs Quality score The Jadad score, with a scale of 1–5 (score of 5 being the or those under development in terms of clinical relevance best quality), was used to assess the quality of studies con- for the management of COPD. cerning the likelihood of biases related to randomization, double blinding, withdrawals, and dropouts.9 Studies were Materials and methods considered of high quality if they had a Jadad score $3. Two Review questions reviewers independently assessed the quality of individual Is the evidence for the efficacy of LABA/LAMA FDCs for studies, and any difference
Load more

Recommended publications
  • Fluticasone Furoate and Vilanterol for the Treatment of Chronic Obstructive Pulmonary Disease
    Expert Review of Respiratory Medicine ISSN: 1747-6348 (Print) 1747-6356 (Online) Journal homepage: http://www.tandfonline.com/loi/ierx20 Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock To cite this article: Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock (2017): Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease, Expert Review of Respiratory Medicine, DOI: 10.1080/17476348.2017.1386564 To link to this article: http://dx.doi.org/10.1080/17476348.2017.1386564 Accepted author version posted online: 28 Sep 2017. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierx20 Download by: [Imperial College London Library] Date: 29 September 2017, At: 01:13 Publisher: Taylor & Francis Journal: Expert Review of Respiratory Medicine DOI: 10.1080/17476348.2017.1386564 Review Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori1*, Paolo Ruggeri1, Paolo Casolari2, Kian Fan Chung3, Giuseppe Girbino1, Ian M. Adcock3. 1Unità Operativa Complessa di Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF) Università degli Studi di Messina, Italy. 2Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Ferrara, Italy. 3Airways Disease Section, National Heart and Lung Institute, Royal Brompton Hospital Biomedical Research Unit, Imperial College London, UK.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • 15-CLASSIFICATION of DRUG Adrenergic Nonsel Αadr Antag
    15-CLASSIFICATION OF DRUG Adrenergic nonsel αadr antag-dibenamine, ergot alkaloid(ergotamine, ergosine, ergocornine, ergocristine, ergocryptine), phenoxybenzamine(irrevers), phentolamine, tolazoline sel α1adr agonist-mephentermine, metaraminol, phenylephrine, methoxamine, midodrine, naphazoline, oxymetazoline, xylometazoline sel α1adr antag-prazosin, indoramin, terazosin, doxazosin, alfuzosin, tamsulosin, silodosin, urapidil sel α2adr agonist-apraclonidine, clonidine, methyldopa, guanfacine, guanabenz, moxonidine, rilmonidine, brimonidine, tizanidine, dexmedetomidine sel α2adr antag-yohimbine, idazoxan, mianserine, mirtazapine, tianeptine, amineptine nonsel βadr agonist-isoprenaline nonsel βadr antag-pindolol(intrinsic sympathomimetic activity, max bioavail), Nadolol(loNgest), propranolol(max LA activity), oxprenolol, timolol sel β1adr agonist-dobutamine sel β1adr antag-eSmolol(Shortest), atenolol(min prot binding), metoprolol(max interindividual variation), acebutolol, bisoprolol, celiprolol, nebivolol(3rd gen), betaxolol sel β2adr agonist-terbutaline, ritodrine, orciprenaline(metaproterenol), salbutamol(albuterol), salmeterol, fenoterol, isoetharine, dopexamine(β2,D1) sel β2adr antag-butoxamine sel β3adr agonist-sibutramine Adrenocortical suppression steroid(prednisone, hydrocortisone, dexamethasone), aminoglutethimide, fludrocortisone, ketoconazole, megestrol, metyrapone, mitotane Alzheimer ds antiAChE synth-tacrine, donepezil, rivastigmine, eptastigmine, metrifonate natural-galantamine antioxidant-vitD,E MAOI-selegiline acetyl L carnitine
    [Show full text]
  • WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/141069 Al 18 September 2014 (18.09.2014) P O P C T (51) International Patent Classification: Novartis Pharmaceuticals Corporation, 150 Industrial A61K 9/00 (2006.01) A61K 31/00 (2006.01) Road, San Carlos, California 94070 (US). A61K 9/16 (2006.01) (74) Agent: MAZZA, Michael; Novartis Vaccines and Dia (21) International Application Number: gnostics, Inc., 4560 Horton Street, Emeryville, California PCT/IB2014/059632 94608 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 11 March 2014 ( 11.03.2014) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/784,865 14 March 2013 (14.03.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant (for all designated States except US) : NO¬ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (CH).
    [Show full text]
  • Download Download
    IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F4/2019.4 Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Katrin Altosaar1, Poornima Balaji2, Richard A. Bond3, David B. Bylund4, Susanna Cotecchia5, Dominic Devost6, Van A. Doze7, Douglas C. Eikenburg8, Sarah Gora6, Eugénie Goupil6, Robert M. Graham2, Terry Hébert6, J. Paul Hieble9, Rebecca Hills10, Shahriar Kan6, Gayane Machkalyan6, Martin C. Michel11, Kenneth P. Minneman12, Sergio Parra3, Dianne Perez13, Rory Sleno6, Roger Summers14 and Peter Zylbergold6 1. Boehringer Laboratories, LLC, USA 2. Victor Chang Cardiac Research Institute, Australia 3. University of Houston, USA 4. University of Nebraska, USA 5. Université de Lausanne, Switzerland 6. McGill University, Canada 7. University of North Dakota, USA 8. University of Houston College of Pharmacy, USA 9. GlaxoSmithKline, USA 10. University of Edinburgh, UK 11. Johannes Gutenberg University, Germany 12. Emory University, USA 13. Cleveland Clinic Lerner Research Institute, USA 14. Monash University, Australia Abstract The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [58], see also [180]. Adrenoceptors, α1 α1-Adrenoceptors are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. phenylephrine, methoxamine and cirazoline are agonists and prazosin and cirazoline antagonists considered 3 125 selective for α1- relative to α2-adrenoceptors. [ H]prazosin and [ I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bodipy PLprazosin- QAPB) are used to examine cellular localisation of α1-adrenoceptors. Selective α1- adrenoceptor agonists are used as nasal decongestants; antagonists to treat hypertension (doxazosin, prazosin) and benign prostatic hyperplasia (alfuzosin, tamsulosin).
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Newer Therapies in COPD
    CHAPTER Newer Therapies in COPD 50 Prem Parkash Gupta INTRODUCTION therapies are available for the patients with difficulties in Chronic Obstructive Pulmonary Disease (COPD), a smoking cessation like withdrawal symptoms. In some common preventable and treatable disease, is characterized countries, influenza and pneumococcal vaccinations are by persistent airflow limitation that is usually progressive also recommended as a preventive therapy as a part of and associated with an enhanced chronic inflammatory National Guidelines. response in the airways and the lung to noxious particles PHARMACOTHERAPIES ESTABLISHED IN VARIOUS or gases. Exacerbations and comorbidities contribute significantly to the overall severity in individual patients. GUIDELINES COPD affects nearly 8% of the world’s population Primary intention of any pharmacological therapy in concerning 160 million people. COPD is a leading cause COPD is to reduce symptoms, decrease the frequency of morbidity and mortality worldwide and results in an and severity of exacerbations, and improve health related economic and social burden that is both substantial and quality of life status and exercise tolerance. COPD increasing. The prevalence of COPD is directly related to medicines available presently have not been conclusively the prevalence of tobacco smoking (being the strongest shown to modify the long-term decline in lung function risk factor ever known), although, outdoor, occupational that is the hallmark of this disease. The recommended and indoor air pollution are also major COPD risk factors. medications as per Global Initiative for Chronic The burden of COPD is likely to increase in the coming Obstructive Lung Disease (GOLD) Guidelines (2016) are decades due to continued exposure to COPD risk factors mentioned in tabular form in Table 2.
    [Show full text]
  • Ultra Labas in COPD
    Ultra LABAs in COPD Puneet Saxena Changing the Natural History • Smoking cessation • LTOT • LVRS in selected patients • Pharmacotherapy? •Anthonisen NR. The lung health study. JAMA. 1994 •Nocturnal Oxygen Therapy Group, et al. Ann Intern Med. 1980 •Naunheim KS. Ann Thorac Surg. 2006 • Post hoc analysis of the TORCH study • Effects of – combined salmeterol 50 μg plus fluticasone propionate 500 μg – either component alone – Placebo • On the rate of post-bronchodilator FEV1 decline in patients with moderate or severe COPD • 5,343 patients were studied Celli BR et al. Am J Respir Crit Care Med. 2008 Adjusted yearly rate of decline in FEV1 by treatment group Celli BR et al. Am J Respir Crit Care Med. 2008 Search for the ‘Holy Grail’ • Ideal Bronchodilator – Long acting – Instant action – Minimal side effects • LABA • LAMA • Ultra-LABA Need for Ultra LABAs • Importance of once daily dosing – Noncompliance – increased morbidity in COPD • Potency – binding ability and local concentration • Onset of action – water solubility of the molecule • Better β2:β1 profile • Retrospective study - 55,076 COPD patients • Adherence was strongly correlated with dosing frequency • PDC was 43.3%, 37.0%, 30.2% and 23.0% for QD, BID, TID, and QID patient cohorts • Adherence was correlated with healthcare resource utilization • For 1000 COPD patients, a 5% point increase in PDC reduced the annual number of inpatient visits (2.5%) and emergency room visits (1.8%) Toy EL et al. Respir Med. 2011 Scientific rationale Mechanism of action Approved Ultra-LABAs • Indacaterol:
    [Show full text]
  • WO 2016/142708 A2 15 September 2016 (15.09.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/142708 A2 15 September 2016 (15.09.2016) P O P C T (51) International Patent Classification: (74) Agent: A.A. THORNTON & CO.; 10 Old Bailey, Lon A61K 9/127 (2006.01) A61K 31/00 (2006.01) don EC4M 7NG (GB). A61K 9/19 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 16/050645 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) Date: International Filing DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 9 March 2016 (09.03.2016) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 770/MUM/2015 10 March 2015 (10.03.2015) ΓΝ TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: CIPLA LIMITED [IN/IN]; Cipla House Pen (84) Designated States (unless otherwise indicated, for every insula Business Park, Ganpatrao Kadam Marg, Lower kind of regional protection available): ARIPO (BW, GH, Parel, Mumbai 400 013 (IN).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Newer Bronchodilators
    NEWER BRONCHODILATORS Dr R Lakshmi Narasimhan SR Pulmonary Medicine Topics to be covered • Ultra LABA (+/-ICS) • Newer LAMA • LAMA + LABA • Novel Bronchodilators Why the need for newer BD? • OD dosing convenient and hence improves compliance and adherence • BDs that provide rapid relief provide patients with reassurance after first dose and thus also improve compliance • BDs with rapid onset of action also suitable for asthma • Once-daily agents may also affect stability of airway tone, with reduced fluctuations in airway patency leading to increased morning FEV1 Murphy et al. Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Drugs (2014) 74:1635–1657 Ultra long acting Beta 2 Agonists • Indacaterol • Vilanterol • Olodaterol • Carmoterol • Milveterol • Abediterol • GSK-642444 • PF-610355 Indacaterol • QAB-149 • First once daily ultra-LABA to be developed • Approved for COPD in Europe in 2009, US and Japan in 2011, and China in 2012 Pharmacology • Fast onset of action* • Sustained bronchodilation (~24 hrs)** – Lipophilic – remains membrane bound – High intrinsic affinity to Beta2 receptors • Delivered via Breezhaler® single dose DPI device • 150, 300 mcg capsules *Balint B et al. INSURE Trial. Int J Chron Obstruct Pulmon Dis. 2010;5:311–8. **Laforce C et al. INTEGRAL study. Pulm Pharmacol Ther. 011;24(1):162–8. Other potential mechanisms • Anti-inflammatory effect • Anti-tumour effect • May inhibit NF-kB activity and MMP-9 pathway preventing lung damag
    [Show full text]